Covx Technologies Ireland Limited

Pfizer Healthcare Ireland

Pfizer Corporation

Olivier Alexandre Laurent

David Tumelty

Abhijit Suresh Bhat

Alice Lee

Richard Ryan Preston

Wei Hong Yu

Mark John Pozzo

Palani Balu

Curt William Bradshaw

Anna Maria Tempczyk-Russell

Rory Francis Finn

Haim Moskowitz

Jin Xie

Moorthy Sitharamaiah Suriyanarayana Palanki

Nancy Jane Levin

Jie Huang

Gregory Allan Waszak

Lauren Diane Wood

Joseph Patrick Martin, Jr

Nicholas Gary Luksha

Gopinath Vedachalam Annathur

Anna Tempczyk-russell

Anna Tempczyk-Russell

The present invention relates to a polypeptide comprising 7 &#x3b2;-strands A, B, C, D, E, F, and G sequentially connected together by connecting chains of amino acids, and a first &#x3b1;-helix sequentially located on the EF chain between &#x3b2;-strands E and F, wherein the &#x3b2;-strands are arranged so as to form a first &#x3b2;-sheet comprising &#x3b2;-strands A, B, D, and E, and a second &#x3b2;-sheet comprising &#x3b2;-strands C, F and G, said first and second &#x3b2;-sheets being covalently bonded together so as to form a first Ig domain; wherein the EF chain between &#x3b2;-strands E and F comprises the sequence X-X-X-X-KH(SEQ ID NO:98), and X, Xand Xare each independently any amino acid residue, characterized in that Xis selected from the group consisting of A, G, I, V, L, R, S, T, Q, P, N, M, H, W, and pharmaceutically acceptable salts, stereoisomers, tautomers, solvates, and prodrugs thereof.

Mutant antibodies and conjugation thereof

The present invention provides a composition of the formula: [FGF21-1Linker]-[Ab]-[2-Linker-Ex4]; wherein FGF21 is an FGF21 homologue; and Ex4 is an Exendin4 homologue; and Ab is an aldolase catalytic antibody or antigen binding portion thereof; and the 1linker is covalently attached to the side chain of a protein-linking residue in FGF21 and to a combining site of the antibody, and the 2linker is covalently attached to the side chain of a peptide-linking residue in Ex4 and to a combining site of the antibody, and wherein the first and second linker are the same or different. Various uses of the compounds are provided, including methods to prevent or treat diabetes or diabetes-related conditions.

Anti-diabetic compounds

The present invention relates to Multifunctional Antibody Conjugates, comprising an antibody or antigen binding portion thereof, comprising at least a fragment of a light chain constant kappa region (CL&#x3ba;) comprising Kaccording to Kabat numbering; a linker comprising the formula X-Y-Z, wherein Z is a group is covalently connected to the antibody through the side chain of K, Y is a linear or branched biologically compatible connecting chain, and X is a group covalently connected to at least one Effector Moiety. The invention further provides specific MAC compounds and compositions of the invention.

Multifunctional antibody conjugates

Growing community of inventors

San Diego, CA, United States of America

Olivier Alexandre Laurent